These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30391093)

  • 1. Supply and demand for hemophilia treatments-Systems-based approaches to mitigate the risk.
    Stoffman JM; Jackson S; Teitel J
    Transfus Apher Sci; 2018 Dec; 57(6):731-734. PubMed ID: 30391093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
    Pierce GF; Lusher JM; Brownstein AP; Goldsmith JC; Kessler CM
    JAMA; 1989 Jun; 261(23):3434-8. PubMed ID: 2498537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor products in the treatment of hemophilia.
    Miller KL
    J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: Blood fractions for haemophilia.
    Aledort LM
    Lancet; 1974 Dec; 2(7894):1452. PubMed ID: 4140363
    [No Abstract]   [Full Text] [Related]  

  • 6. [Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].
    Medarde A; Ayesa C; Alfonso L; Muñóz A
    Sangre (Barc); 1979; 24(5-C):942-6. PubMed ID: 121170
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia management in transfusion medicine.
    Poon MC; Card R
    Transfus Apher Sci; 2012 Jun; 46(3):299-307. PubMed ID: 22503305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII/factor IX prophylaxis for severe hemophilia.
    Carcao M; Srivastava A
    Semin Hematol; 2016 Jan; 53(1):3-9. PubMed ID: 26805901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Complexity in Hemophilia Management.
    Croteau SE
    Pediatr Clin North Am; 2018 Jun; 65(3):407-425. PubMed ID: 29803274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The demand for factor VIII and for factor IX and the toll fractionation product surplus management.
    Calizzani G; Profili S; Candura F; Lanzoni M; Vaglio S; Cannata L; Liumbruno GM; Franchini M; Mannucci PM; Grazzini G
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s64-76. PubMed ID: 24333316
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene therapy for hemophilia.
    Pipe SW
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29077262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries.
    O'Mahony B; Noone D; Prihodova L
    Haemophilia; 2015 Jul; 21(4):436-43. PubMed ID: 25996253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hemophilia in France.
    Allain JP
    Thromb Haemost; 1976 Jun; 35(3):553-8. PubMed ID: 989961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
    Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
    Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentrated therapeutic fractions of coagulation factors prepared in Europe.
    Soulier JP
    Thromb Diath Haemorrh Suppl; 1967; 26():391-400. PubMed ID: 6064869
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances toward gene therapy for hemophilia at the millennium.
    Kaufman RJ
    Hum Gene Ther; 1999 Sep; 10(13):2091-107. PubMed ID: 10498242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII supply for haemophilia.
    Carter J; Chapman C; Fong R
    N Z Med J; 1989 Jun; 102(870):326. PubMed ID: 2500623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.